Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms

  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Demajo, Santiago
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Pinyol, Magda
  • García, Noelia
  • Capdevila, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Suárez-Cisneros, Helena|||0000-0003-4636-2106
  • Shimada, Mariko
  • Karube, Ken
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Colomer, Dolors|||0000-0001-7486-8484
  • Beà, Sílvia
  • Martin-Subero, Jose Ignacio|||0000-0001-8809-5195
  • Campo, Elias|||0000-0001-9850-9793
  • Jares, Pedro
Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored. Here, we investigated the transcriptional role of cyclin D1 in lymphoid tumor cells with cyclin D1 oncogenic overexpression. Cyclin D1 showed widespread binding to the promoters of most actively transcribed genes, and the promoter occupancy positively correlated with the transcriptional output of targeted genes. Despite this association, the overexpression of cyclin D1 in lymphoid cells led to a global transcriptional downmodulation that was proportional to cyclin D1 levels. This cyclin D1-dependent global transcriptional downregulation was associated with a reduced nascent transcription and an accumulation of promoter-proximal paused RNA polymerase II (Pol II) that colocalized with cyclin D1. Concordantly, cyclin D1 overexpression promoted an increase in the Poll II pausing index. This transcriptional impairment seems to be mediated by the interaction of cyclin D1 with the transcription machinery. In addition, cyclin D1 overexpression sensitized cells to transcription inhibitors, revealing a synthetic lethality interaction that was also observed in primary mantle cell lymphoma cases. This finding of global transcriptional dysregulation expands the known functions of oncogenic cyclin D1 and suggests the therapeutic potential of targeting the transcriptional machinery in cyclin D1-overexpressing tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cyclin D1 Overexpression Predicts Poor Disease-Specific Survival in Human Papillomavirus-Independent Vulvar Squamous Cell Carcinoma

  • Carreras-Dieguez, Núria|||0000-0002-4809-8102
  • Ordi, Oriol
  • Peñuelas, Núria|||0000-0001-6443-9790
  • del Pino, Marta|||0000-0003-2178-2403
  • Diez-Ahijado, Laia
  • Darecka, Katarzyna
  • Marimón, Lorena|||0000-0002-2943-3550
  • Vega, Naiara
  • Torne, Aureli|||0000-0003-4700-9507
  • Saco, Adela
  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Gaba, Lydia
  • Rakislova, Natalia|||0000-0001-5030-3526
The amplification of CCND1 is associated with the development and progression of various cancers. In a recent study, we showed that almost all adverse outcomes in vulvar squamous cell carcinomas (VSCC) occurred in patients with human papillomavirus (HPV)-independent, TP53-mutated tumors harboring CCND1 gains. In this study, we analyzed the association between CCND1 gain, cyclin D1 immunohistochemistry (IHC), and disease-specific survival (DSS) in a series of patients with HPV-independent VSCC. All patients who underwent primary surgery for VSCC at the Hospital Clínic of Barcelona, Spain, from 1975 to 2023 were recruited ("overall" cohort, n = 139). IHC for p53 and cyclin D1 was performed in all cases. In a subset of patients, we performed DNA sequencing to evaluate CCND1 copy number variations ("sequencing" cohort, n = 54). Cyclin D1 IHC overexpression (≥50% of tumor cells) had 94% sensitivity and 67% specificity as a surrogate marker of CCND1 gain. In the "sequencing" cohort, only CCND1 gains were significantly associated with impaired DSS in the multivariate analysis (hazard ratio [HR], 4.15; 95% CI, 1.08-5.40; P =.032), whereas stage or mutant TP53 status did not reach statistical significance. In the "overall" cohort, advanced stage (HR, 2.41; 95% CI, 1.08-5.39; P =.032) and cyclin D1 IHC overexpression (HR, 4.89; 95% CI, 1.77-18.5; P =.001) were associated with worse DSS in the multivariate analysis, whereas abnormal p53 IHC was not (HR, 5.06; 95% CI, 0.68-647; P =.138). In conclusion, cyclin D1 overexpression is an acceptable surrogate for CCND1 gain and has a much stronger adverse prognostic impact than altered p53 IHC in patients with HPV-independent VSCC.